# BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

> **NCT01938846** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 90 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BI 860585
- **DRUG:** exemestane
- **DRUG:** BI 860585
- **DRUG:** BI 860585
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01938846
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-05
- **Primary completion:** 2016-07-30
- **Final completion:** 2017-06-22
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938846, "BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01938846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*